Other Clinical Trial - Almonertinib With Chemotherapy in mEGFR NSCLC

Status Active, not recruiting

Clinical Trial Summary

The reason for the study is to find out if an experimental combination of an oral medication called Almonertinib when used in combination with chemotherapy is more effective for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR).

Clinical Trial Description

In total the study aims to enroll approximately 36 patients who will receive almonertinib in combination with chemotherapy in the main trial. The study involves a Screening Period, Treatment Period, and Follow up Period. Whilst receiving study medication, it is expected patients will attend, on average, approximately 15 visits over the first 12 months and then approximately 4 visits per year afterwards. Each visit will last about 2 to 6 hours depending on the arrangement of medical assessments by the study centre. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-Small Cell Lung Cancer Metastatic

Clinical Trial Details

NCT number	NCT04646824
Study type	Interventional
Source	Tianjin Medical University Cancer Institute and Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 19, 2020
Completion date	November 25, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01523340` - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting	`NCT03956641` - Evolution of the Physical Condition in Treated Cancer Patients	N/A
Active, not recruiting	`NCT02035683` - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy	N/A
Completed	`NCT01848613` - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC	Phase 4
Suspended	`NCT01320501` - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer	Phase 4
Terminated	`NCT01471964` - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT06127940` - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation	Phase 1
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Terminated	`NCT03445000` - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer	Phase 2
Terminated	`NCT03386929` - Survival Prolongation by Rationale Innovative Genomics	Phase 1/Phase 2
Recruiting	`NCT02922764` - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer	Phase 1
Terminated	`NCT01574300` - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Completed	`NCT01966003` - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT03656094` - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors	Phase 2
Terminated	`NCT01348126` - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT03469960` - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr	Phase 3
Recruiting	`NCT05919264` - FOG-001 in Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04793815` - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	N/A
Terminated	`NCT01380795` - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas	Early Phase 1
Completed	`NCT02959619` - Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK	Phase 1